Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 9,701–9,800 of 10,906
Malakooti, S. K., Abboud, M., Murphy, J. E., Singer, N. G., & McComsey, G. A. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108540
Salehi, M., Darazam, I., Nematollahi, A., Alimohammadi, M., Pouya, S., Alimohammadi, R., Khajavirad, N., Porgoo, M., Sedghi, M., Sepahi, M., et al. (2023) · medRxiv · doi:10.1101/2023.11.01.23297898
Machine Learning-guided Prediction of Ionizable Amphiphilic Janus Dendrimers for mRNA Nanomedicine
Cheng, W.-T., Zheng, H.-L., Zhu, P.-Y., Hao, J., Zhang, D., & Li, Y.-S. (2026) · Chinese Journal of Polymer Science · doi:10.1007/s10118-026-3563-3
COVID-19 Vaccines: Fabrication Techniques and Current Status
Kaur, L., Mahajan, A., Singh, G., Dhawan, R. K., Singh, L., & Kaur, A. (2021) · Coronaviruses · doi:10.2174/2666796702666210728150704
Ding, K., Naqvi, O. H., Seeberger, R. J., Bratzler, D. W., & Wendelboe, A. M. (2024) · Emerging infectious diseases · doi:10.3201/eid3011.231582
Personalized mRNA therapy comes of age in melanoma
Lu, S., Micevic, G., & McGrath, J. A. (2026) · British Journal of Dermatology · doi:10.1093/bjd/ljag378
Tuba, S., Widyati, Sulaiman, S. A. S., & Hasibuan, A. K. H. (2022) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2022.1010003 · Cited by 1
Marcellus, Voss, C. J. D., Li, S., Ateere, A., McShane, H., & Stylianou, E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1807190 · Cited by 2
Adler, A. C., & Lin, E. E. (2021) · British Journal of Anaesthesia · doi:10.1016/j.bja.2021.01.025
Ansari, F., Salehi‐Pourmehr, H., Pashazadeh, F., Mahdavi, N., Atayi, M., Armand, N., & Pourjafar, H. (2025) · Current Nanoscience · doi:10.2174/0115734137365213250612113303
Kustova, D. D., Pochtovyi, A. A., Геннадьевна, Ш. О., Shtinova, I. A., Kuznetsova, N. A., Клейменов, Д. А., Komarov, A. G., & Gushchin, V. А. (2024) · Problems of Virology · doi:10.36233/0507-4088-242
Boldyrev, I. A., Shendrikov, V. P., Vostrova, A. G., et al. (2023) · Биоорганическая химия · doi:10.31857/s0132342323020069
Yang, J., Hao, Y., Long, S., Huang, Y., Wang, G., Yan, C., Piao, J., Wu, B., Huang, G., & Han, X. (2026) · Lab on a Chip · doi:10.1039/d6lc00536e
Franco, J. E. M. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/174883 · Cited by 1
Amphiphilic guanidine-based lipids enhance mRNA delivery and immune activation
Wei, Q., Li, R., Fan, J., Xu, M., Yuan, P., Liu, J., Wang, Q., Shen, Y., Slater, N. K. H., & Tang, J. (2026) · Biomaterials Science · doi:10.1039/d6bm00068a
A single-nucleotide change in the Kozak sequence enhances protein expression from IVT mRNA
Knol, R. A., Fariaby, T., de Vlieger, E. A., van Santbrink, P., Kros, A., & Slütter, B. (2026) · Molecular Therapy — Nucleic Acids · doi:10.64898/2026.05.20.726450
Baldari, C., Leone, C., Leccese, G., Stradis, C. D., Invidia, A., Quintarelli, C., Angelis, B. D., Locatelli, F., Gigli, G., Maiorano, G., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71640 · Cited by 1
“…the most successful non-viral platforms, LNPs have gained widespread attention, particularly after their clinical success in mRNA vaccines [28] (mRNA-1273 and BNT162b2) [27, 29, 30], and are currently under extensive clinical investigation for cancer immunotherapy and infectious diseases [31–33].”
Ultrasound-assisted antifouling for continuous microfluidic manufacturing of RNA–LNP
Hwang, Y., Kim, G., Dinh, H., et al. (2026) · Lab on a Chip · doi:10.1039/d6lc00340k
Traditional Therapies Involving Nutrition for the Management of COVID-19
Ramesh, M., Muthuraman, A., & Anand, K. (2023) · Coronaviruses · doi:10.2174/0126667975250575231018111950
Chen, X., Fang, J., Ge, X., Li, M., Jiang, F., Yang, L., Hong, L., & Liu, Z. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115148 · Cited by 5
Incidence and severity of SARS-CoV-2 infections in people with primary ciliary dyskinesiaPreprint
Pedersen, E. S. L., Schreck, L. D., Goutaki, M., Bellu, S., Copeland, F., Lucas, J. S., Zwahlen, M., COVID-PCD patient advisory group, & Kuehni, C. E. (2022) · medRxiv · doi:10.1101/2022.10.14.22281075 · Cited by 1
Highlights from Stanford Drug Discovery Symposium 2021
Chase, A. J., Malhotra, S. V., Mercola, M. A., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab250
Fan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2026) · eLife · doi:10.7554/elife.108959.2 · Cited by 1
Syed, A. A., Eqbal, F., Shamsi, H. R., Syed, A. R. S., Zakir, S. J., Fawzy, M., & Khan, K. S. (2024) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2024.102343 · Cited by 1
SARS-CoV-2 vaccines breakthrough infection hospitalizations after one dose in Libya: cohort studyPreprint
Abdelhamid, M. H. M., Almsellati, I. A., Annajar, B. B., Abdelhamid, A. H., Alemam, H. A., & Etikar, M. (2021) · medRxiv · doi:10.1101/2021.09.26.21263691
Cross-clade protection against human H5N1 isolates by a clade 2.3.4.4b HA mRNA vaccine in mice
Shichinohe, S., Li, Q., Tanaka, H., Anindita, J., Yoshimoto, S., Kaewaroon, N., Shimooka, M., Anzai, I., Akita, H., & Watanabe, T. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129215
Junkins, E. J., Chehab, S., Lee, K. M. N., & Clancy, K. B. H. (2023) · doi:10.31234/osf.io/vs2uf
Navarro, B. O. (2023) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/192635
Vacunación contra SARS-COV-2: un año después de iniciada en Colombia
Pinzón, J. E. D. (2022) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1350
Karim, Q. A., Baum, F. E., & Detels, R. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198816805.002.0013
What is a breakthrough infection? 6 questions answered about catching COVID-19 after vaccination
Mishra, S. (2021) · The Conversation · doi:10.64628/aai.cjq6epsqu · Cited by 1
Nanoscale Vaccines for the Prevention of COVID-19
Iqbal, M. J., Hamdani, T., Attarwala, H. Z., & Amiji, M. M. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-39020-3_13
County-Level Vaccination Coverage and Rates of COVID-19 Cases and Deaths in the United StatesPreprint
McLaughlin, J. M., Khan, F. L., Pugh, S. J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3908476
The Frankensteinification of Translational Gerontology
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0004
Yuan, Z., Wong, I., Xu, R., Zhang, X. Z., & Lei, C. L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1612205
van de Schepop, L., Sentí, M. E., Volmerink, N., Wang, F., Mirzahossein, E., Smits, S. M., Seinen, C. W., Stecker, K. E., van Ravensteijn, B. G. P., Vader, P., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7450764
Wu, J., Meng, H., Guo, X., Liu, L., Zhou, G.-H., Liu, W., Qi, X.-Y., & Li, J.-X. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128575
Non-invasive nanoparticle barcoding in nonhuman primates
Jang, B., Zenhausern, R., Lian, L., Gentry, K., Abbas, A. M., Rudden, S., Shin, Y.-J., Doan, J., Loughrey, D., Curran, E. H., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03262-6 · Cited by 1
Gadelha, C. S. E., Terreri, M. T., Burian, A. P. N., da Fraga, A. C. M., Machado, K. L. L. L., Silva, R. E. C. D. F., Ferreira, D. B., Moraes, Y. O. G., Ribeiro, S. L. E., Telles, C. M. P. F., et al. (2026) · Pediatric Research · doi:10.1038/s41390-026-04836-5
SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 – June 30, 2021
Darby, B. J., Alexander, V., & Murphy, J. M. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.041
Graham, J. P., Arteaga, A., Moghaddam, A. S., Spiller, K. L., Laverty, D. J., & Gonzalez‐Fernandez, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.29.728905 · Cited by 1
“21,22 Yet, LNPs are inherently immunogenic, helping to mount a response to the delivered spike protein and initiate antibody production.”
Banerjee, A., Garg, R., Liu, Q., van Kessel, J., Asavajaru, A., Uhlemann, E.-M. E., Joessel, M., Hamonic, G., Khatooni, Z., Kroeker, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3656968/v1
Ethnological aspects of COVID-19
Dhiman, P., & Bhatia, M. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e20975
ВАКЦИНАЦІЯ ВІД СОVID-19: ОЧІКУВАННЯ, РЕАЛІЇ І ПЕРСПЕКТИВИ
Івахів, О. Л., Vyshnevska, N. Y., & Іщук, І. С. (2021) · Інфекційні хвороби · doi:10.11603/1681-2727.2021.1.11951
Weiner, D. B., Jansen, K. U., & Villafana, T. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00068-2
Vaccine Responses in Early Age
Parvathaneni, S., Sakai, J., Liu, L., & Akkoyunlu, M. (2026) · Vaccines · doi:10.3390/vaccines14070629
“Neutralizing antibody levels measured 57 days after the second dose were comparable to those of young adults who were previously shown to be protected from COVID-19 following two 100 µ g doses of mRNA-1273 vaccine [117].”
Las vacunas contra la COVID-19, ¿cuál es mejor?
González-Ortiz, J. A., Xibille-Friedmann, D. X., & Lopez, D. A. O. (2022) · Lux Médica · doi:10.33064/49lm20223129 · Cited by 1
Assessing Faculty for Universities: Beyond Publishing Metrics
Chakrabarti, S. S., Kaur, U., Patwardhan, K., & Chakrabarti, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-4060-4_6
Maister, A., Zakai, T. G., Fried, C., Petersiel, N., Mousa, A., Bishop, B., Korytny, A., Zeidan, M., Rozenberg, G., & Neuberger, A. (2026) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-025-00286-9
Gong, D., Xie, X., Tang, J., Li, S., & Li, H. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag092 · Cited by 1
“The recent successful deployment of LNPs as delivery vehicles for COVID-19 mRNA vaccines (mRNA-1273 and BNT162b2) in the immunoprophylaxis of SARS-CoV-2 infection has generated substantial interest in R NA-LNPs delivery systems [9, 10].”
Liao, S., Chang, W.-J., Hsu, C.-Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4001816
Singh, P., Choudhary, R., Matreja, P. S., Patrick, S., Kumar, D., & Singh, V. K. (2023) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/jcmk/13528
Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs
Jin, Y., Luedtke, A. R., Moodie, Z., Janes, H., & Benkeser, D. C. (2026) · Statistics in Medicine · doi:10.1002/sim.70495
Self-citation悠, 松., 喬之, 鈴., 拓磨, 中., 明日美, 水., 雄太, 小., 琢真, 佐., & 峰司, 早. (2024) · Nihon Kyukyu Igakukai Zasshi Journal of Japanese Association for Acute Medicine · doi:10.1002/jja2.12883
Guillain-Barré Syndrome Post Covid-19 Vaccination: An Overview
Salazar, M. A. N. (2022) · Open access Journal of Neurology & Neurosurgery · doi:10.19080/oajnn.2022.17.555962
Haider, S., Ullah, S., Wasim, A., et al. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100363
Impact of Ebola virus nucleoprotein on VP40 virus-like particle production: a computational approachPreprint
Liu, X., Stahelin, R. V., & Pienaar, E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.09.552607
Utilizing the K18-hACE2 mouse model to develop protective COVID-19 vaccines
Wong, T. Y. (2022) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.11414
Elko, E., Nelson, G. A., Mead, H., et al. (2022) · medRxiv · doi:10.1101/2022.01.24.22269542 · Cited by 1
Haldar, R., Halder, P., & Mahanayak, B. (2026) · Discover Public Health · doi:10.1186/s12982-026-01657-z
Possible Mechanisms of mRNA-LNP Degradation: A Comprehensive Review
Khan, M. F. H., Islam, T., Mishra, A., & Kamen, A. (2026) · Vaccines · doi:10.3390/vaccines14070620 · Cited by 1
“They are considered an innovative approach for immunization and have emerged as a promising alternative to traditional vaccines [1]. mRNA vaccines from Pfizer/BioNTech and Moderna have significantly changed the course of the SARS-CoV-2 pandemic [2,3].”
Sasaki, N., Kuroda, R., Tsuno, K., Imamura, K., & Kawakami, N. (2022) · medRxiv · doi:10.1101/2022.02.24.22271484
A biomimetic delivery strategy for achieving dual-specific lipid nanoparticle targeting
Duan, Y., Zhang, F., Guerrero, E. D., Sung, Y., Tian, Z., Wang, X., Basak, P., Chatterjee, S., Farbiak, L., & Siegwart, D. J. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100554
Wang, S., Jing, S., Zou, S., Zhang, Y., Ge, M., Gao, K., Li, X., Zhao, L., & Wang, J. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70160
“The remarkable success of mRNA vaccines during the COVID-19 pandemic has accelerated the maturation of mRNA vaccine technology, 33,34 promoting its broader application in cancer research and offering a promising avenue for cancer prevention and treatment. this hypofractionated approach aligns with…”
RNA-Based Therapies for Treating Monogenic Cardiomyopathies
Edwards, J. J., Edelson, J. B., & Rossano, J. W. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.12.040 · Cited by 1
Ohtsuka, J., Fukumura, M., Imai, M., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3802855
Kastl, A., Weaver, K. N., Zhang, X., et al. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12142
Wu, X., Yao, J., Qian, J., Huang, Q.-F., Deng, T., Xu, S.-Q., Wang, H.-F., Li, Q., Peng, J., Yang, Y., et al. (2022) · Journal of Acute Disease · doi:10.4103/2221-6189.336575
Ghosh, S. K., Adhikari, A., Mukhopadhyay, A., Bose, S., & Sharma, K. (2022) · Springer eBooks · doi:10.1007/978-981-16-9336-6_12
Decoy therapeutics for COVID-19 and influenza: principles and translation
Liang, J., Zhang, Z., Xu, Y., Mubareka, S., Rotstein, O. D., & Zhang, H. (2026) · Trends Open · doi:10.1016/j.treopn.2026.07.008
Ateş, A. K. (2025) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1734697
Overview of COVID-19 Vaccine Hesitancy in Low- and Middle-Income Countries
Khwaja, H. (2022) · Altamash Journal of Dentistry and Medicine · doi:10.65037/ajdm.2022.012.78
Survival and Incidence of COVID-19 After SARS-CoV-2 Vaccination in a Series of 2391 Cancer PatientsPreprint
Heudel, P., Favier, B., Solodky, M.-L., Assaad, S., Chaumard, N., Trédan, O., Bachelot, T., Ray-Coquard, I. L., Russias, B., Fournier, M.-L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3968882
Takano, T., Matsumura, T., & Takahashi, Y. (2026) · International Immunology · doi:10.1093/intimm/dxag040 · Cited by 1
Mravčík, V., Valachovičová, S. K., & Vobořil, J. (2022) · Central European Journal of Public Health · doi:10.21101/cejph.a7230
Sun, Y., Kunanusorn, P., Tup, K. M., Chokkakula, S., & Yang, B. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1859541 · Cited by 1
Ye, T., Alamgir, A., Robertus, C. M., Colina, D., Monticello, C., Donahue, T. C., Hong, L., Vincoff, S., Goel, S., Fekkes, P., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec8271 · Cited by 9
Biotecnología y vacunas COVID-19
Carlucci, A. M., Cozza, S. A. B., Barberis, M. L., et al. (2022) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/revhospitalbaires.v42i4.238
Prieto-Campo, Á., López‐Durán, A., Roque, F., Herdeiro, M. T., Figueiras, A., & Zapata‐Cachafeiro, M. (2026) · BMC Public Health · doi:10.1186/s12889-026-26674-0
“…also expressed safety concerns about the vaccine’s speed of development and the possibility that it might not have complied with all the required stages, as compared to that of traditional vaccines which have been on the market far longer and have undergone testing for a period of years [27–29].”
Yang, Y., Park, H., Li, C., Song, D., & Wang, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-082988
Single-cycle SARS-CoV-2 vaccine elicits high protection and sterilizing immunity in hamstersPreprint
Lett, M. J., Otte, F., Hauser, D., Schön, J., Kipfer, E. T., Hoffmann, D., Halwe, N. J., Ulrich, L., Zhang, Y., Cmiljanović, V., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.17.541127 · Cited by 2
Lacoux, C., Villes, V., Riegel, L., Coulmain, S., Lorente, N., Derras, S. E., Castro, D. R., Roux, P., Delabre, R. M., & Michels, D. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-01096-6
Seto, K., Ohashi, Y., Masuda, J., & Terakado, H. (2022) · Global Health & Medicine · doi:10.35772/ghm.2022.01024
Tumor Acidity-Activatable Ionizable Lipid Nanoparticles for Selective Oncolytic Therapy
Zhang, H., Du, R., Zhiyi, L., Ge, J., Su, C., 周火生, Wang, F., Bao, Y., Luo, D., Luo, D., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c07591
Alzahrani, W. M. (2023) · Cardiometry · doi:10.18137/cardiometry.2023.26.168176 · Cited by 1
Considerations for Coronavirus Disease 2019 Vaccination Among B-Cell-Depleted Patients
Ammitzbøll, C. G., Thomsen, M. K., Erikstrup, C., & Troldborg, A. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.09.006 · Cited by 1
Risk of COVID-19 infection among frontline healthcare workers during the COVID-19 pandemic
Abhilash, K. P. P., Nellimootil, M. V., Binila Chacko, I., et al. (2025) · World Journal of Virology · doi:10.5501/wjv.v14.i2.99663
COVID-19 mRNA vaccines and their applications in chronic liver diseases
Zhu, J. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2020-0001
The Impact of Coronavirus Disease 2019 Vaccines on the Immune System: A Narrative Review
Urazayeva, S. T., & Tussupkaliyeva, K. (2025) · West Kazakhstan Public Health Journal · doi:10.4103/wkpj.wkpj_3_26
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.